KR20200109932A - Amnion ring and preparation method thereof - Google Patents

Abstract

The present invention relates to an amnion ring which can be used in the treatment of ocular surface diseases, and a manufacturing method thereof. The amnion ring according to the present invention, in the amnion transplantation field for the purpose of healing wounds of the cornea, minimizes complications due to sutures since suturing of the transplanted amnion is not necessary, and also can be conveniently used in the outpatient clinic by having a form of a lens. Furthermore, it is possible to fix the amnion ring in the form of the lens without a separate O-ring, to greatly reduce foreign body sensation and discomfort when inserting the same into the eyeball since a polyvinyl alcohol hydrogel coating layer is located on the surface of a support, and thus to allow the amnion ring to be located in the center of the eyeball without deviating.

Description

Amnion ring and its manufacturing method {AMNION RING AND PREPARATION METHOD THEREOF}

The present invention relates to an amnion ring that can be used in the treatment of ocular surface diseases and a method of manufacturing the same, and more particularly, to an amnion ring in which an amnion, which is a biological material, is fixed in a ring shape, and a manufacturing method thereof.

In the ophthalmic area, the cornea is a transparent tissue that causes reduced vision and corneal opacity due to scar formation. In this wound healing process, amnion is widely used to control scar formation. The amniotic membrane is the innermost membrane of the placenta and surrounds the fetus, and acts as a barrier to protect the fetus from various infections and immune responses from the mother. The amnion has a thickness of 0.2 to 0.5 mm, thin and translucent, consists of a simple cuboidal epithelium, a thick basement membrane, and avascular mesenchymal stroma, and has no smooth muscle cells, nerves, lymphatic vessels and blood vessels Therefore, it is a biological membrane that does not show rejection even after transplantation. The amniotic membrane promotes epithelialization in the wound healing process, reduces inflammation, and inhibits angiogenesis, thereby inhibiting scar formation. After the effects of such amniotic membranes were known, good results have been obtained by transplanting amniotic membranes in various ophthalmic diseases. In particular, the effects of rapid wound healing and excellent corneal opacity reduction by transplanting amniotic membranes to surface diseases of the cornea and conjunctiva have been reported.

As described above, it is known that the amniotic membrane maintains the characteristics of normal epithelial cells, promotes epithelial cell growth, and has anti-inflammatory action, angiogenesis inhibitory action, and scar formation inhibition action. As a mechanism of action, the amniotic membrane acts as a basement membrane that can maintain the growth and characteristics of cornea and conjunctival blast cells. Therefore, in the case of repeated persistent corneal epithelial detachment accompanied by partial corneal limbal deficiency or corneal ulcer, transplantation of the amniotic membrane onto the cornea can cause the cornea. The function of epithelial hair cells is restored to regenerate a healthy ocular surface, and it can promote the growth of corneal epithelium during persistent corneal epithelial defects or recurrent corneal erosion. In addition, since the amniotic membrane acts as a basement membrane, it helps the movement and differentiation of the epithelium, strengthens the adhesion of the basal epithelial cells, inhibits apoptosis of the epithelium, and promotes epithelial regeneration in the wound healing process.

In addition, the amniotic membrane exhibits anti-inflammatory action by down-regulating IL-1, IL-8, PMN elastase, Gro-alpha (growth regulated oncogene-alpha), and Neutrophil activating peptide-78 (ENA). It is also known to adsorb cells and induce apoptosis of inflammatory cells, preventing inflammatory cells from penetrating into wound tissue.

Looking at the history and research trends of the use of the existing amniotic membrane, De Rotth in 1940 used a live fetal membrane with amnion and chorionic membrane to reconstruct the surface of the conjunctiva (Non-Patent Document 1), and Sorsby et al. 1946. Amnion was used for eye burn treatment (Non-Patent Document 2). In 1965, Ropen-Hall used the amniotic membrane as a temporary patch after chemical eye burns (Non-Patent Document 3). Since then, the amniotic membrane has been used for various purposes such as dressing of wounds after skin burns or skin transplants, implantation in peritoneal defects during surgical open surgery, or implantation in middle ear cavity and synovial sac surgery.

In recent years, it has been actively researched and used ophthalmologically, such as replacing the conjunctiva, promoting corneal wound healing, and improving the microenvironment of corneal epithelial stem cells to treat corneal limbal deficiency.

However, until now, the use of amnion for the purpose of corneal wound healing has a problem that requires suturing to implant the amnion itself onto the wound, which may cause complications during the suture process, and it is difficult to use it repeatedly after transplanting. Its use has been limited.

In an effort to compensate for this problem, U.S. Patent No. 7,494,802 discloses that the amniotic membrane is physically fixed using an O-ring on a polycarbonate body having a hole of 15 to 16 mm for use after ophthalmic surgery. An example is disclosed. Similarly, Korean Patent Registration No. 10-1132625 discloses a lens in which an amnion is fixed using an O-ring.

However, such a product is not only uncomfortable due to the feeling of foreign body in the eyes due to the hard polycarbonate, and there is a problem that the fixture is shifted from the center of the eyeball to one side due to blinking of the eyelids.

US Patent No. 7,494,802 Korean Patent Registration No. 10-1132625

De Rotth A. Arch. Opthalmol., 1940; 23:525-5 Sorsby A, Symons HM. Opthalmol., 1946; 20:337-345 Ropen-H MJ, Trans Ophthalmol Soc UK, 1965;85:631-646 Kenyon KR et al., Ophthalmology., 1985; 92:1461-1470 Stark T et al., Cornea., 1991;10:196-202 Allan BD short P, Crawford CJ, et al., Br.J. Ophthalmol., 1993:77:698-701 Chen PP, Ariyasu RG, Kaza V, et al., Am.J. Ophthalomol., 1995; 120: 151-160 Tan DT et al., Arch. Ophthalmol., 1997; 115: 1235-1240 Ti SE Chee SP et al., Br.J. Ophthalmol., 2008; 84:385-389. Sridhar MS et al., Cornea., 2002; 21:305-307 Koranyi G et al., Br. J. Ophthalmol., 2004; 88:911-914 Uy HS Reyes JM et al., Br. J. Ophthamol., 2005; 112:667-671 Shimmura S, Shimazaki J, Ohashi Y, et al., Cornea., 2001; 20: 408-413 Kim JS, Kim JC, Na BK, et al., Exp Eye Res., 2000; 70: 329-337 Gris O, Campo Z. Wolley-Dod C, et al., Cornea., 2002; 21: 22-27 Takano Y, Fukagawa K, Miyake-Kashima M, et al., Cornea., 2004; 233: 723-725 Choi YS, Kim JY, Wu WR, et al., Cornea., 1998; 17:389-395 Woo HM, Kim HS, Kweon OK, et al., Br. J. Opthalmol., 2001; 85: 345-349 Batlle JF, Perdomo FJ. Opthalmol., 1993; 100:107 Kim JC, Tseng SC. Cornea., 1995; 14: 473-484 Akle CA et al., Lancet, 1981; 2:1003-1005 Dua HS et al., Br.J. Opthalmol., 1999; 83:748-752 Tsuyoshi Yoshita et al., Am. J. Ophthalmol., Vol. 138, No.3: 486-487 Gowri Pachigolla et al., Eye & Contact Lens, vol 35, No4, 2009 Noriko Koizumi et al., Current Eye Research, vol. 20, No. 3. 173-177, 2000

Therefore, the present invention directly adheres and fixes the amnion to the ring-shaped hydrogel that can be applied to the eye, so that a separate O-ring for fixing the amnion to the support is not required, and inconvenience such as foreign body feeling when inserting the eyeball is avoided. We want to provide an amnion ring that can be well positioned in the center of the eyeball even without it.

In order to achieve the above object, the present invention is a support in the form of a ring having a polyvinyl alcohol hydrogel coating layer on the surface; And a contact lens-shaped amnion having a circumferential edge attached to the polyvinyl alcohol hydrogel coating layer on the support.

In order to achieve the above other object, the present invention comprises the steps of: (1) coating the surface of the support in the form of a ring with polyvinyl alcohol hydrogel to prepare a support in the form of a ring having a polyvinyl alcohol hydrogel coating layer; (2) placing the amnion so as to be in contact with the polyvinyl alcohol hydrogel coating layer on the support while covering one surface of the support, and forming the amnion to have a contact lens shape before or after placing the amnion; And (3) attaching the amniotic membrane to the polyvinyl alcohol hydrogel coating layer by crosslinking the resultant of step (2).

The amniotic membrane ring according to the present invention minimizes complications due to suturing because suturing of the implanted amniotic membrane is unnecessary in the field of amniotic membrane transplantation for the purpose of healing wounds on the cornea, and has a lens shape, so that it can be conveniently used in an outpatient area. Furthermore, it is possible to fix the amniotic membrane in the form of a lens without a separate O-ring, and a polyvinyl alcohol hydrogel coating layer is located on the surface of the support to greatly reduce foreign body sensation and discomfort when inserting the eyeball. It can be located without leaving.

1 and 2 are cross-sectional views of a molding mold used in manufacturing an amnion ring according to the present invention.
3 is a perspective view of a support used in manufacturing the amnion ring according to the present invention.
4 is a cross-sectional view of a punch-type cutting blade used when manufacturing an amnion ring according to the present invention.
5 is a schematic diagram of an amnion ring according to an embodiment of the present invention.
6 is a graph showing the cell viability for cytotoxicity after 24 hours and 48 hours, as a result of the cytotoxicity evaluation for the amniotic membrane ring of Example 1 (see Evaluation Example 2).
7 is a result of evaluating the graft rejection reaction to the amniotic membrane ring of Example 1, the amniotic membrane and polyvinyl alcohol hydrogel were separated from the amniotic membrane ring, and each was implanted subcutaneously in the rat, followed by time (1 week, 2 weeks and 4 weeks) This is a photograph showing the degree and condition of transplantation over the course of (see Evaluation Example 3).

The present invention is not limited to the contents disclosed below, and may be modified in various forms unless the gist of the invention is changed.

In the present specification, "including" means that other components may be further included unless otherwise specified. In addition, all numbers and expressions representing amounts of components, reaction conditions, and the like described in the present specification are to be understood as being modified by the term "about" in all cases unless otherwise specified.

Amnion Ring

The present invention is a support in the form of a ring having a polyvinyl alcohol (PVA) hydrogel coating layer on the surface; And a contact lens-shaped amnion having a circumferential edge attached to the polyvinyl alcohol hydrogel coating layer on the support.

Hereinafter, with reference to FIG. 5, the amnion ring will be described in detail.

The positive film ring 500 includes a ring-shaped support 51 having a PVA hydrogel coating layer 52. The support 51 increases the mechanical strength of the amniotic membrane ring 500 and allows it to be positioned without being separated by being in close contact with the center of the eyeball having a curve when the eyeball is inserted.

The support 51 may be made of one or more materials selected from the group consisting of polycarbonate, polyethylene, acrylic, polytetrafluoroethylene, and polymethyl methacrylate, and specifically polyethylene.

The supporter 51 may have a ring shape, but may have a trapezoidal shape having a convex curve in a thickness direction in a longitudinal section. A perspective view of an example of the supports 51 and 300 is shown in FIG. 3. Referring to FIG. 3, the outer circumferential surfaces of the supports 51 and 300 have a predetermined height 33 and bent, and have a narrower upper inner diameter 31 and a wider lower outer diameter 32. Specifically, the support (51, 300) has an upper inner diameter 31 of 17 to 25 mm, or 17 to 19 mm and a lower outer diameter 32 of 19 to 30 mm, or 19 to 23 mm, 0.5 to 2.5 mm, or has a height 33 of 0.5 to 2 mm, and may have a radius of curvature of 2 to 15 mm, or 2 to 10 mm in the bend.

The support 51 may have 3 to 10 or 3 to 6 holes 34 formed in a row along the outer peripheral surface of the ring, and when within the above range, the roughness of the outer peripheral surface of the support 51 is increased. It allows the PVA hydrogel coating layer 52 to be well attached to the outer peripheral surface of the support 51. If the number of holes 34 exceeds 10, the strength of the support 51 may be weakened, and if less than 3, the bonding strength between the PVA hydrogel coating layer 52 and the support 51 decreases and may be separated from each other. have.

The hole 34 may have a shape such as a circle or an ellipse, and may have a diameter of 0.1 to 1.0 mm, 0.3 to 0.8 mm, or 0.3 to 0.6 mm.

The PVA hydrogel coating layer 52 surrounds the entire surface of the support 51, and the circumferential edge of the contact lens-shaped amnion 53 is attached to the PVA hydrogel coating layer. The PVA hydrogel coating layer 52 has a thickness of 0.1 to 2.0 mm, or 0.5 to 1.0 mm. When it is within the above range, there is little feeling of foreign body when the eye is inserted.

The amniotic membrane 53 may be obtained from humans or cattle, and may be separated from the placenta after cesarean section of a mother whose serological test results such as hepatitis B, hepatitis C, HIV, syphilis, etc. are negative. The amnion used in the amnion ring may be one or two or more overlapping ones.

The amnion ring 500 is a form in which the PVA hydrogel coating layer 52 and the amnion 53 are directly attached without a crosslinking agent, and may be manufactured by the following method.

Amniotic Manufacturing method

The present invention comprises the steps of: (1) coating the surface of a ring-shaped support with polyvinyl alcohol (PVA) hydrogel to prepare a ring-shaped support having a polyvinyl alcohol hydrogel coating layer; (2) positioning the amnion so as to contact the PVA hydrogel coating layer on the support while covering one surface of the support, and forming the amnion to have a contact lens shape before or after placing the amnion; And (3) attaching the amnion to the PVA hydrogel coating layer by crosslinking the resultant of the step (2).

First, according to the manufacturing method of the amnion ring of the present invention, the amnion can be prepared as follows. The amniotic membrane may be obtained from humans or cows as described above, and after separating from the placenta after cesarean section of a mother whose serological test results such as hepatitis B, hepatitis C, HIV, syphilis, etc. are negative, washing and sterilization You can get it.

For example, after washing the mother's amniotic membrane several times with sterile physiological saline and sodium hypochlorite, the substrate layer of the amniotic membrane is removed with a scraper, and then washed several times with sterile physiological saline, and then nitrocellulose ( After attaching to nitrocellulose) paper, it can be cut into about 4x5cm size and stored in a DMEM (Dulbecco modified eagle medium) cryopreservation solution containing 20 to 50% by weight of glycerol and stored in a freezer below -40°C until use.

At this time, glycerol is more advantageous in terms of the stability of the amnion when it is within the above range, and when used in excess of the above range, a problem of cytotoxicity is caused, and when it is used below the above range, the amnion is formed by crystallization of the cryopreservation solution. It can be damaged.

The PVA hydrogel can be prepared by the following method.

First, a soft PVA hydrogel is prepared. PVA hydrogel can be prepared by a first melting step using a bath and a second melting step using high pressure sterilization. Specifically, after putting a solid PVA having a weight average molecular weight of 100,000 to 200,000 Da, or 100,000 to 150,000 Da into a container containing purified water, bathing for 3 minutes to 2 hours while stirring so as not to stick to the bottom of the container, and autoclaving Then, the remaining solid PVA is completely dissolved to prepare a PVA hydrogel. The prepared PVA hydrogel may contain PVA in an amount of 5 to 50% by weight, 5 to 40% by weight, or 10 to 30% by weight. When it is within the above range, mechanical properties are excellent, and an appropriate viscosity suitable for coating a support can be maintained. If it is used less than the above range, the mechanical properties are deteriorated, and if it is used in excess, the viscosity is excessively high, and the coating operation is not smooth.

The support has an upper inner diameter of 17 to 25 mm, or 17 to 19 mm and a lower outer diameter of 19 to 30 mm, or 19 to 23 mm by molding raw materials of the material as described above by a high pressure injection machine, and 0.5 to 2.5 It has a height of mm, or 0.5 to 2 mm, and can be manufactured to have a radius of curvature of 2 to 15 mm, or 2 to 10 mm in bending.

Using the PVA hydrogel as described above, coating the surface of the ring-shaped support as described above to form a PVA hydrogel coating layer (step (1)), and forming an amnion so as to contact the PVA hydrogel coating layer on the support. After positioning (step (2)), chemical and/or physical crosslinking treatment is performed to attach the amnion to the PVA hydrogel coating layer (step (3)).

The steps (1) and (2) may be performed in a molding mold.

Referring to FIG. 1, the molding mold 100 may be a lens molding mold, and may include an upper plate 11, a pillar 12, and a lower plate 13.

The mold 100 may be made of at least one material selected from the group consisting of acrylic, acetal, polytetrafluoroethylene, polymethyl methacrylate, polycarbonate, stainless steel, and titanium, but is not limited thereto.

The upper plate 11 of the mold has a 16 to 18 mm diameter hole in which the center pillar 12 will be located, and when combined with the lower plate 13, 1 to 10 cm ³ or 3 between the upper plate 11 and the lower plate 13 A space of to 5 cm ³ may be created. When within the above range, the PVA hydrogel coating layer formed on the support may have an appropriate thickness.

A portion where the lower plate 13 and the pillar 12 of the mold are coupled, for example, the convex portions 121 of the pillar 12 and the concave portions 131 and 132 of the lower plate 13 are magnets 14 and 15 A may be further provided, and the pillar 12 may be erected on the lower plate 13 by magnetic force by the magnets 14 and 15.

In this case, the central portion of the concave portion 131 formed on one surface of the lower plate 13 may have a concave shape such as a circle or an ellipse for coupling with the pillar 12.

The concave portion 132 formed on the other surface of the lower plate 13 may be provided with a magnet 15.

The convex portion 121 of the pillar 12 may have a convex shape such as a circular shape or an ellipse so as to correspond to the concave portion 131 of the lower plate 13, and the convex portion 121 is the concave portion 131 It may be equal to or smaller than the contact area of ).

The step (1) and/or step (2) may be performed in the molding mold as described above.

Specifically, in the case of step (1), after inserting the support 51 into a mold, it may be performed by injecting PVA hydrogel around the support body 51.

More specifically, the prepared amnion 53 is placed on the lower plates 13 and 23 of the mold so that the upper part of the support 51 faces downward. The amnion 53 may be laid with a substrate layer or an epithelial layer facing upward. In order to fix the amniotic membrane 53 and the support 51, the convex portions 121 and 221 of the pillar are coupled to the recessed portions 131 and 231 of the lower plate to fix the amniotic membrane 53. The amnion 53 may be formed into a contact lens shape by combining the convex portions 121 and 221 of the pillar and the concave portions 131 and 231 of the lower plate. During the above process, the amnion 53 may be positioned using tweezers. Then, the PVA hydrogel may be evenly injected between the amnion 53 and the lower plates 13 and 23 of the mold and along the outer circumferential surfaces of the pillars 12 and 22 to coat the surface of the support 51.

Then, the PVA hydrogel coating layer 52 on the support 51 and the amnion 53 are in contact with each other while spreading it toward the circumferential surface of the column as if pulling the edge of the amnion 53 using tweezers, and then the mold top plate 11, 21), the edge of the amnion 53 formed in the shape of a contact lens is strongly attached to the PVA hydrogel coating layer 52 once more so that the amnion 53 covers one surface of the support 51, while the support ( 51) to be attached to the PVA hydrogel coating layer 52 on.

In addition to this method performed in a mold, the support is coated on the surface of the support by immersing the support in a container containing the PVA hydrogel for a certain period of time, and then an amnion molded in the shape of a contact lens is attached, or a contact lens after attaching the amnion. It is also possible to perform a process of forming into a shape.

Then, the resultant of the step (2) is chemically and/or physically crosslinked to attach the amnion and the PVA hydrogel coating layer so that they do not separate (step (3)) to prepare the desired amnion ring.

The crosslinking treatment may be performed by chemical crosslinking or physical crosslinking as follows, but is not limited thereto.

The chemical crosslinking is carbodiimide, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (1-ethyl-3-(3-dimethylamonopropyl) carbodiimide; EDC, EDAC), glutaraldehyde ( Glutaraldehyde), boric acid, borax (borax), formaldehyde (formaldehyde) and hexamethylene diisocyanate (hexamethylene diisocyanate, HMDI) in a solution containing at least one selected from the group consisting of (2) This can be done by immersing the resulting product.

The physical crosslinking may be performed by freeze-thawing, ultraviolet irradiation, radiation irradiation, or dehydration heat treatment.

The freeze-thawing may be performed by repeating the process of freezing for 2 to 18 hours at 20 to -80°C and melting for 1 to 6 hours at 20 to 36°C 1 to 10 times, and irradiation of 2.5 to 50 It may be performed by irradiating a gamma ray, electron beam, or the like at a dose of kGy, or 15 to 25 kGy. When it is within the above range, the mechanical strength of the PVA hydrogel coating layer is increased to an appropriate level (a degree to which a foreign body sensation or dryness is not felt when inserted into the eye), and the adhesion to the amniotic membrane is improved, and thus it is not separated.

After the step (3), the step of cutting the outline of the amnion ring and/or the step of sterilizing the amnion ring may be further performed. Specifically, the crosslinked amniotic membrane ring can be separated from the mold and then cut in a circular shape along the outline of the amniotic membrane ring using a punch-type cutting blade (see FIG. 4), surgical scissors, and a scalpel.

The cut amnion ring can be washed several times with purified water or physiological saline, and then sterilized by irradiating with gamma rays, electron beams, etc. at a dose of 5 to 35 kGy, or 15 to 25 kGy.

As described above, the amniotic membrane ring according to the present invention minimizes complications due to suturing since suturing of the implanted amniotic membrane is not required in the field of amniotic membrane transplantation for the purpose of healing wounds of the cornea, and has a lens shape so that it can be conveniently used in the outpatient area. have. Furthermore, it is possible to fix the amniotic membrane in the form of a lens without a separate O-ring, and a polyvinyl alcohol hydrogel coating layer is located on the surface of the support to greatly reduce foreign body sensation and discomfort when inserting the eyeball. It can be located without leaving.

The above will be described in more detail by the following examples. However, the following examples are for illustrative purposes only, and the scope of the examples is not limited thereto.

[ Example ]

Manufacturing example 1: Amnion preparation

The amniotic membrane was processed in compliance with the rules on human tissue safety in accordance with the Korean Human Tissue Safety and Management Act.

Specifically, the amniotic membrane was separated from the placenta obtained after cesarean section of a mother without infectious diseases such as hepatitis B, hepatitis C, acquired immunodeficiency syndrome (AIDS, HIV), and syphilis. The amniotic membrane was repeatedly washed several times in sterile physiological saline and sodium hypochlorite solution, and finally, repeatedly washed with sterile physiological saline. After washing, the amniotic membrane was placed in a cryopreservation solution mixed with DMEM (Dulbecco modified eagle medium) and glycerol at 4:1 (v/v) and stored in a freezer below -40°C until use. After dissolving in physiological saline, the cryopreservation solution was removed and used.

Manufacturing example 2: Polyvinyl alcohol ( PVA ) Hydrogel Produce

PVA is used with a molecular weight of 130,000 Da, added to purified water at a ratio of 20% (w/w), heated for 30 minutes, autoclaved at 121°C for 20 minutes to completely dissolve and subdivide into disposable syringes. It was stored so as not to harden in a heating block of 80°C or higher before.

Manufacturing example 3: Molding mold Preparations

For the production of the amnion ring, a molding mold including an upper plate, a lower plate and a column having the following sizes and/or shapes was prepared.

The upper plate has an upper diameter of 46 mm, a height of 24.6 mm, and a hole having a diameter of 17.7 mm in a central portion to which the pillars are to be joined.

On one side of the lower plate, a circular concave portion having a diameter of 10.1 mm for fixing the column and a concave portion equipped with a magnet are formed on the other side.

The pillar has a diameter of 17.6 mm, and is combined with a concave portion on one side of the lower plate, but has a convex portion equipped with a magnet.

Manufacturing example 4: Support preparation

The support was manufactured by a high-pressure injection molding machine using polyethylene raw materials.

The support had an upper inner diameter of 18.3 mm, a lower outer diameter of 21.6 mm, and a height of 1.5 mm. The radius of curvature outside the support was 8 mm, and three holes of 0.6 mm in diameter were provided at intervals of 120°.

Example One : Amniotic Produce

Using the raw materials and molds prepared in Preparation Examples 1 to 4, an amnion ring was manufactured in the following manner.

The amnion was fixed by placing the upper inner diameter of the support on the lower plate of the mold so that the upper inner diameter of the support faces downward, and the amnion was placed on the support so that the epithelial layer of the amnion faces upward. Then, the PVA hydrogel was slowly injected between the amnion and the support, and when the PVA hydrogel was injected around the entire support, the amnion was spread horizontally using tweezers, and the upper mold was bonded to the lower plate to completely adhere the amnion to the mold.

Then, the amnion and the PVA hydrogel coating layer were physically crosslinked and bonded by a freeze-thawing method. Specifically, in order to prevent moisture evaporation of the amnion and PVA hydrogel coating layer during crosslinking, place the mold on an aluminum tray, cover it with a cover, wrap it with aluminum foil, and freeze it at -40°C for 6 hours, and then at room temperature of 20 to 25°C. The thawing process for 6 hours was repeated a total of 5 times to perform crosslinking treatment.

Thereafter, the crosslinked result (a state in which the amnion is attached to the PVA hydrogel coating layer) was cut off the outline of the amnion ring using a punching-type cutting blade (inner diameter of 21.5 mm). At this time, one side of the amnion attached to the lower plate of the mold was spread out with tweezers facing up, and the outline of the amnion ring was cut using a press machine. The cut amnion rings were washed repeatedly 5 times at 100 to 120 rpm for 10 minutes using 50 ml physiological saline per one. The amniotic membrane ring after washing was put in sterile physiological saline and sterilized by irradiating gamma rays (or electron beams of the same dose) at a dose of 15 to 25 kGy.

[ Evaluation example ]

Evaluation example 1: foreign body feeling evaluation

The amniotic membrane ring produced in Example 1 was evaluated for 3 days in a foreign body sensation caused by the application of the amniotic membrane ring to the eye of 10 ordinary people. 5 out of 10 patients applied an amniotic ring to the right (R1, R3, R5, R7, R9), and the other 5 to the left (L2, L4, L6, L8, L10) eye, and the other eye with a therapeutic lens. The foreign body feeling to the amnion ring was relatively compared. All 10 patients were asked to live their daily lives after applying amnion rings and therapeutic lenses, and artificial tears were administered every 2 hours.

The evaluation was performed using a visual analog scale (VAS), which is a subjective pain scale method, and according to the degree of feeling of a foreign body, 0 points (no foreign body sensation), 1 point (a foreign body sensation but no pain), 2 points (a foreign body sensation and pain, but patient) , 3 points (uncomfortable with foreign body sensation and pain), 4 points (different body sensation and pain, and difficulty to endure) were evaluated on the 1st, 2nd, and 3rd days after application of the amnion ring using a questionnaire for foreign body sensation. It is shown in Table 1 below.

Looking at the results in Table 1, all 10 subjects of the experiment felt a foreign body sensation due to the initial application of the amniotic membrane ring, and 9 of them responded that pain occurred due to the foreign body sensation, and 5 responded that it was uncomfortable. On the 2nd day, 1 answered that there was no foreign body sensation, 9 of them felt a foreign body sensation, and 4 of them said no pain. Four respondents said they had pain but were patient, and the other one answered that they were uncomfortable with pain. On the 3rd day of the application of the amniotic ring, 4 people did not have a foreign body sensation, and 5 of the remaining 6 responded that they only felt a foreign body sensation but had no pain or were patient, and the other 1 responded that they showed pain due to the foreign body sensation. It was confirmed that the fit was improved.

Evaluation example 2: Cytotoxicity assessment

The amniotic membrane ring prepared in Example 1 was eluted using a DMEM medium containing 10% Fetal Bovine Serum (FBS) to perform a cytotoxicity test. Cells were mouse fibroblast cells (ATCC CCL 1, L929) cell line, and as medium, 5 ml of DMEM (with 10% FBS) per 1 g of amnion ring was added and eluted at 37±1℃ for 24±2 hours. It was taken and used. H ₂ O ₂ was used as a negative control for cell death. Cells obtained through subculture have a concentration of 2.5 x 10 ⁴ (cells/ml) in 300 ul of DMEM medium containing 10% FBS. After inoculation, the cells were added to each well of a 48-well plate and cultured for 24 hours.After confirming that the confluency of the cells was 80% or more, the culture medium of each well was removed, and only 10% FBS was included. The positive control group, the negative control group, and the test group elution medium using DMEM medium were each treated with 300 ul and cultured. Cell viability was analyzed for cell viability using the MTT assay according to standard protocols. After 24 hours and 48 hours of culture, the medium in the wells was removed, 300 ul of MTT solution (0.5 mg/ml) was added to each well, and incubated for 2 hours, and then the medium in the well plate was removed and 200 ul of DMSO was added to each well. Formazan was dissolved by adding to the well, and the cell viability was evaluated by measuring the hop intensity at a wavelength of 540 nm with a spectrophotometer. The results are shown in FIG. 6.

Looking at the results of FIG. 6, the survival rates of the positive control group and the test group showed no significance (∵ p>0.05) at 24 hours and 48 hours, showing similar survival rates, indicating that there was no cytotoxicity.

Evaluation example 3: Evaluation of transplant rejection response

The amnion ring prepared in Example 1 above was implanted under the skin of a rat (Samtaco Bio Korea) by separating the amnion and the PVA hydrogel coating layer in a sterile table. At this time, the PVA hydrogel coating layer means only PVA that does not include a support. After 1, 2 and 4 weeks, the tissue was collected and fixed with formalin, washed with water and paraffin embedding, cut into 5 um thickness, stained with Hematoxyline & Eosin (H&E) (H&E stain Kit, Thermo scientific). , The degree of inflammation was investigated using an optical microscope. The results are shown in FIG. 7.

Referring to the results of FIG. 7, after the amniotic membrane and PVA were transplanted, the degree of inflammation to the periphery of the transplant was observed insignificantly after 1 and 2 weeks, and no inflammatory reaction or foreign body reaction was observed after 4 weeks. In addition, in the case of the amniotic membrane, a large number of cells were observed around the amniotic membrane 1 week after transplantation, and the surrounding cells penetrated into the amniotic membrane after 2 weeks, and more cells penetrated into the amniotic membrane after 4 weeks. Can be seen.

100, 200: mold for molding
11, 21: top 12, 22: pillar
13, 23: lower plate 14, 15, 24, 25: magnet
121, 221: convex portion 131, 132, 231, 232: concave portion
300, 51: support
31: upper inner diameter 32: lower outer diameter
33: height 34: hole
500: amnion ring
52: polyvinyl alcohol hydrogel coating layer
53: amniotic membrane

Claims (21)

A ring-shaped support having a polyvinyl alcohol hydrogel coating layer on its surface; And
Containing, an amnion ring in the shape of a contact lens having a circumferential edge attached to the polyvinyl alcohol hydrogel coating layer on the support. The method of claim 1,
The support is made of at least one material selected from the group consisting of polycarbonate, polyethylene, acrylic, polytetrafluoroethylene and polymethyl methacrylate, amnion ring. The method of claim 1,
The longitudinal section of the support is a trapezoidal shape having a convex curve in the thickness direction, amnion ring. The method of claim 3,
The support has an upper inner diameter of 17 to 25 mm, a lower outer diameter of 19 to 30 mm, and a height of 0.5 to 2.5 mm, and has a radius of curvature of 2 to 15 mm in the bend. The method of claim 1,
The support has 3 to 10 holes formed in a line along the outer circumferential surface of the ring. The method of claim 5,
The diameter of the hole is 0.1 to 1.0 mm, amnion ring. The method of claim 1,
The amniotic membrane is obtained from humans or cattle, amniotic membrane ring. The method of claim 1,
The amniotic membrane is overlapped with two or more layers, amniotic membrane ring. The method of claim 1,
The polyvinyl alcohol hydrogel coating layer has a thickness of 0.1 to 2.0 mm. The method of claim 1,
The polyvinyl alcohol hydrogel coating layer and the amnion are directly attached without a crosslinking agent, an amnion ring. (1) preparing a ring-shaped support having a polyvinyl alcohol hydrogel coating layer by coating the surface of the ring-shaped support with polyvinyl alcohol hydrogel;
(2) placing the amnion so as to be in contact with the polyvinyl alcohol hydrogel coating layer on the support while covering one surface of the support, and forming the amnion to have a contact lens shape before or after placing the amnion; And
(3) crosslinking the resulting product of step (2) to attach the amnion to the polyvinyl alcohol hydrogel coating layer; including, a method of manufacturing an amnion ring. The method of claim 11,
Steps (1) and (2) are performed in a molding mold,
The coating of step (1) is carried out by inserting the support into a molding mold and then injecting polyvinyl alcohol hydrogel around the support. The method of claim 12,
The method of manufacturing an amnion ring, wherein the mold is made of at least one material selected from the group consisting of acrylic, acetal, polytetrafluoroethylene, polymethyl methacrylate, polycarbonate, stainless steel and titanium. The method of claim 12,
The mold includes an upper plate, a lower plate, and a pillar,
A method of manufacturing a positive film ring, in which the pillar is erected on the lower plate by magnetic force. The method of claim 11,
The polyvinyl alcohol hydrogel used in the step (1) contains polyvinyl alcohol in an amount of 5 to 40% by weight. The method of claim 15,
The polyvinyl alcohol has a weight average molecular weight of 100,000 to 200,000 Da, the manufacturing method of the amnion ring. The method of claim 11,
The crosslinking treatment of step (3) is carried out by chemical crosslinking or physical crosslinking. The method of claim 17,
The chemical crosslinking is at least one selected from the group consisting of carbodiimide, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, glutaraldehyde, boric acid, borax, formaldehyde, and hexamethylene diisocyanate. A method of manufacturing an amnion ring, which is performed by immersing the resultant of step (2) in a solution containing. The method of claim 17,
The physical crosslinking is performed by freeze-thawing, ultraviolet irradiation, radiation irradiation, or dehydration heat treatment. The method of claim 11,
After the step (3), further comprising the step of cutting an outline of the amnion ring. The method of claim 11,
After the step (3), the method of manufacturing an amnion ring further comprising the step of sterilizing the amnion ring.

Images